Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard B Warren

Showing results (121-130 of 257) with videos related to

Pageof 26
Sort By:
Dermatology and Therapy|December 11, 2025
Bimekizumab Efficacy and Safety in Patients with Psoriatic Arthritis with Substantial Skin and Nail Psoriasis to 1 YearDiamant Thaçi, Akihiko Asahina, Wolf-Henning Boehncke, et al.
The Journal of Allergy and Clinical Immunology|August 3, 2023
Integrated proteomics and genomics analysis of paradoxical eczema in psoriasis patients treated with biologicsAli Al-Janabi, Paul Martin, Adnan R Khan, et al.
The British Journal of Dermatology|April 29, 2026
Serious infection risk of certolizumab compared with other systemic therapies in women with psoriasisHeber Rew Bright Bright, Catherine H Smith, Philip Laws, et al.
JAMA Dermatology|March 5, 2025
Effectiveness of Adalimumab Biosimilars and Originator for PsoriasisDuc Binh Phan, Anthony P Bewley, Philip Laws, et al.
The British Journal of Dermatology|March 27, 2023
Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trialBruce Strober, Yayoi Tada, Ulrich Mrowietz, et al.
Lancet (London, England)|August 28, 2015
Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritisMeghna Jani, Hector Chinoy, Richard B Warren, et al.
Journal of Drugs in Dermatology : JDD|April 14, 2021
Four-Week Daily Calcipotriene/Betamethasone Dipropionate Foam Is Highly Efficacious in Patients With Psoriasis (PSO-LONG Lead-in Phase)Richard B Warren, Michael Gold, Melinda Gooderham, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 29, 2025
Drug survival of IL-23 and IL-17 inhibitors versus other biologics for psoriasis: A British Association of Dermatologists Biologics and Immunomodulators Register cohort studyLeila Motedayen Aval, Zenas Z N Yiu, Oras A Alabas, et al.
The British Journal of Dermatology|November 11, 2023
Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trialsKenneth B Gordon, Richard G Langley, Richard B Warren, et al.
Dermatology and Therapy|November 22, 2025
Is Cumulative Life Course Impairment Considered in Psoriasis Management? A Multinational Survey of People with Psoriasis and Healthcare ProfessionalsRaymond Matthews, April W Armstrong, Matthias Augustin, et al.
Pageof 26

Showing results (121-130 of 257) with videos related to

Sort By:
Pageof 26
Dermatology and Therapy|December 11, 2025
Bimekizumab Efficacy and Safety in Patients with Psoriatic Arthritis with Substantial Skin and Nail Psoriasis to 1 YearDiamant Thaçi, Akihiko Asahina, Wolf-Henning Boehncke, et al.
The Journal of Allergy and Clinical Immunology|August 3, 2023
Integrated proteomics and genomics analysis of paradoxical eczema in psoriasis patients treated with biologicsAli Al-Janabi, Paul Martin, Adnan R Khan, et al.
The British Journal of Dermatology|April 29, 2026
Serious infection risk of certolizumab compared with other systemic therapies in women with psoriasisHeber Rew Bright Bright, Catherine H Smith, Philip Laws, et al.
JAMA Dermatology|March 5, 2025
Effectiveness of Adalimumab Biosimilars and Originator for PsoriasisDuc Binh Phan, Anthony P Bewley, Philip Laws, et al.
The British Journal of Dermatology|March 27, 2023
Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trialBruce Strober, Yayoi Tada, Ulrich Mrowietz, et al.
Lancet (London, England)|August 28, 2015
Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritisMeghna Jani, Hector Chinoy, Richard B Warren, et al.
Journal of Drugs in Dermatology : JDD|April 14, 2021
Four-Week Daily Calcipotriene/Betamethasone Dipropionate Foam Is Highly Efficacious in Patients With Psoriasis (PSO-LONG Lead-in Phase)Richard B Warren, Michael Gold, Melinda Gooderham, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 29, 2025
Drug survival of IL-23 and IL-17 inhibitors versus other biologics for psoriasis: A British Association of Dermatologists Biologics and Immunomodulators Register cohort studyLeila Motedayen Aval, Zenas Z N Yiu, Oras A Alabas, et al.
The British Journal of Dermatology|November 11, 2023
Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trialsKenneth B Gordon, Richard G Langley, Richard B Warren, et al.
Dermatology and Therapy|November 22, 2025
Is Cumulative Life Course Impairment Considered in Psoriasis Management? A Multinational Survey of People with Psoriasis and Healthcare ProfessionalsRaymond Matthews, April W Armstrong, Matthias Augustin, et al.
Pageof 26